Suppressor of cytokine signaling (SOCS) proteins are indispensable negative regulators of cytokine-stimulated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathways. SOCS proteins (SOCS1-7 and CIS) consist of a variable Nterminal region, a central Src homology-2 (SH2) domain, and a C-terminal SOCS box. The N-terminal region in SOCS1 and SOCS3 includes the so-called kinase inhibitory region that has been shown to inhibit the catalytic activity of JAK2. Here, we present a crystal structure at 2.0 Å resolution of the N-terminally extended SH2 domain of SOCS3 in complex with its phosphopeptide target on the cytokine receptor gp130. The structure reveals that major insertions in the EF and BG loops of the SOCS3 SH2 domain are responsible for binding to gp130 with high affinity and specificity. In addition, the structure provides insights into the possible mechanisms by which SOCS3 and SOCS1 inhibit JAK2 kinase activity.
Introduction
Cytokines such as ciliary neurotrophic factor, leukemia inhibitory factor (LIF), interleukin-2 (IL2), IL6, leptin, and erythropoeitin bind to receptors that activate Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathways, resulting in transcriptional upregulation of genes that control cellular proliferation, differentiation, and survival (Ihle and Kerr, 1995) . In a classic negative feedback system, cytokine stimulation also upregulates transcription of genes encoding SOCS proteins (Alexander and Hilton, 2004) . The SOCS protein family consists of eight members, SOCS1-7 and CIS, that possess a variable N-terminal region, a central SH2 domain, and a C-terminal SOCS box (Hilton et al., 1998) .
Through their SH2 domains, SOCS proteins are recruited to specific phosphotyrosine residues in activated cytokine receptors or in JAKs. Downregulation of signaling pathways by SOCS proteins can occur by at least three distinct mechanisms. First, the SOCS box is capable of recruiting the elongin BC complex to target proteins for ubiquitination and subsequent proteasomal degradation (Alexander and Hilton, 2004) . Second, SOCS1 and SOCS3 contain a region N-terminal to the SH2 domain, the so-called kinase inhibitory region, that has been shown to inhibit the catalytic activity of JAK2 Yasukawa et al., 1999) . Third, SOCS proteins can compete with SH2-containing positive factors for binding to phosphotyrosine residues on activated cytokine receptors.
Gene deletion studies in mice have provided important insights into the in vivo function and specificity of SOCS proteins (Alexander and Hilton, 2004) . SOCS3 2/2 mice are not viable (midgestational lethal), owing to placental abnormalities that are thought to be caused by dysregulated LIF signaling (Roberts et al., 2001; Takahashi et al., 2003) . Targeted gene deletion in the liver of mice has demonstrated that SOCS3 is important for downregulation of IL6 signaling pathways (Croker et al., 2003) . The site of interaction of SOCS3 with gp130, the common cytokine receptor for IL6 and LIF, has been mapped to pTyr757 (Nicholson et al., 2000; Schmitz et al., 2000) . SOCS3 has also been reported to interact with JAK2 , the leptin receptor (Bjorbak et al., 2000; Eyckerman et al., 2000) , the erythropoietin receptor (Sasaki et al., 2000) , and the insulin receptor (Emanuelli et al., 2000; Ueki et al., 2004) .
To elucidate the molecular basis for phosphotyrosine recognition by SOCS3, we have determined the crystal structure of the N-terminally extended SOCS3 SH2 domain in complex with a phosphopeptide representing pTyr757 in gp130. The structure provides the molecular basis for the high-affinity interaction between SOCS3 and gp130, and it offers insights into the mechanisms by which SOCS3 and SOCS1 negatively regulate JAK2 signaling.
Results and Discussion
Crystal Structure of SOCS3-gp130(pTyr757) For structural studies, a murine SOCS3 construct was engineered that lacks the nonconserved N-terminal 14 residues and the C-terminal 40 residue SOCS box, but possesses, along with the SH2 domain (residues 42-185), the kinase inhibitory region (residues 22-31) and the N-terminal SH2 domain extension (residues 32-41). The SOCS3 construct also contains a 23 residue deletion (residues 131-153) within the BG loop of the SH2 domain (SH2 domain nomenclature follows that of Eck et al. [1993] ). This region in SOCS3 contains a PEST sequence (Babon et al., 2005) , which is present in mammalian forms of SOCS3, but is missing in other vertebrate forms. The introduced 23 residue deletion is based on a comparison between the zebrafish and mammalian SOCS3 sequences. This form of SOCS3 will be referred to below as SOCS3D.
An 11 residue phosphopeptide based on the sequence surrounding Tyr757 in murine gp130, 753 STVEpYSTVVHS, was used in cocrystallization trials with SOCS3D. As measured by isothermal titration calorimetry, this phosphopeptide binds to SOCS3 with unusually high affinity for an SH2-phosphopeptide interaction: K d = w70 nM with SOCS3D (w80 nM with an intact BG loop) ( Figure S1 ; see the Supplemental Data available with this article online). Crystals of the *Correspondence: hubbard@saturn.med.nyu.edu SOCS3D-gp130 phosphopeptide complex were obtained at pH 6.5 with one complex in the asymmetric unit. The structure was initially solved by molecular replacement and was subsequently verified with experimental phases from a mercury-derivatized crystal (see Experimental Procedures). The structure has been refined at 2.0 Å resolution to an R value of 24.2% (R free of 27.7%). Data collection and refinement statistics are given in Table 1 .
The crystal structure reveals that the SOCS3 SH2 domain adopts a canonical SH2 domain architecture (Kuriyan and Cowburn, 1997) , with a central, four-stranded b sheet (bA/bG, bB, bC, and bD), flanked by two a helices (aA and aB) ( Figure 1A ). The N-terminal extension, present in SOCS1-3 and CIS, forms a 14 residue a helix (aN), which packs against portions of bB, bC, aB, and the DE loop on the backside (opposite the phosphotyrosine binding surface) of the SH2 domain ( Figure 1A ). Residues 15-28, which include residues 22-28 of the kinase inhibitory region, are disordered.
All 11 residues of the phosphopeptide are ordered in the structure, although most of the contacts with the SH2 domain are made by pTyr757 and the residues Cterminal to pTyr757. Indeed, a C-terminal portion of the phosphopeptide is ''enveloped'' by the EF and BG loops ( Figure 1B ). The total buried surface area in the SOCS3 SH2-gp130 phosphopeptide complex is large-1746 Å 2 -compared to 987 Å 2 for the Src SH2-phosphopeptide complex (Waksman et al., 1993 ) (PDB code 1SPS) and 1339 Å 2 for the SHP2 N-terminal SH2-phosphopeptide complex (Lee et al., 1994 ) (PDB code 1AYA); the SH2 domains of SOCS3 and SHP2 have been shown to have overlapping specificities (De Souza et al., 2002) . The only known SH2-phosphopeptide interaction with a larger buried surface area is the SAP SH2-SLAM phosphopeptide complex (Poy et al., 1999) , with 1821 Å 2 buried (PDB code 1D4W). Despite the larger buried surface area, the measured affinity of the SAP SH2-phosphopeptide interaction (K d = w150 nM) (Li et al., 1999) is less than that of SOCS3-gp130
The specific contacts between the SOCS3 SH2 domain and the gp130 phosphopeptide are extensive (Figure 2) and explain the high affinity and specificity of this SH2-phosphopeptide interaction. The phosphate group of pTyr757 binds in the canonical phosphate binding pocket of the SOCS3 SH2 domain, salt bridged to SH2-invariant Arg71 (bB5) (Figure 2A ). Like SHP2, but unlike other SOCS proteins, the SOCS3 SH2 domain contains a glycine (Gly53) at position aA2 rather than the semiconserved arginine. As a consequence, the position of the phosphate group relative to the phenolic ring of the phosphotyrosine is inverted, as observed in the SHP2 SH2-phosphopeptide structure (Lee et al., 1994) . Arg94 in bD (bD6) is also salt bridged to the phosphate group, and its guanidinium group stacks with the phenolic ring of pTyr757. In total, seven direct hydrogen bonds are made to the phosphate group by SH2 domain residues (Figures 2A and 2C) .
N-terminal to pTyr757 of the gp130 phosphopeptide, Val755 (P22 residue relative to pTyr757) makes van der Waals contacts with Gly53 (aA2), the position usually occupied in SH2 domains by an arginine. C-terminal to the phosphotyrosine, the P+3 residue, Val760, is situated in the canonical P+3 binding pocket of the SH2 domain, formed between the EF and BG loops and between bD and aB. The EF loop in the SOCS3 SH2 domain contains a 7 residue insertion relative to Src and SHP2 (see Figure 3A for alignment) that ''drapes'' over the phosphopeptide in the structure ( Figure 1A , right) and contributes six hydrogen bonds to the interaction ( Figures 2B and 2C ). In contrast, for most SH2 domains (e.g., Src and SHP2), the EF loop does not make appreciable contact with the phosphopeptide. The EF loop in the SAP SH2 domain, which also contains a sizable (6 residue) EF loop insertion, makes three hydrogen bonds with the phosphopeptide (Poy et al., 1999) . Of particular note for SOCS3, recognition of His762, the P+5 residue of the phosphopeptide, is achieved through side chain hydrogen bonding with Ser106 in the EF loop (EF2) and with Tyr127 in aB (aB9) (Figures 2B and 2C) . A salt bridge between Asp107 (EF3) and Arg109 (EF5) within the EF loop likely functions to stabilize its conformation.
The BG loop in SOCS3 is of exceptional length, being 37 and 34 residues longer than in Src and SHP2, respectively ( Figure 3A ). The beginning of the BG loop, just after the end of aB, is disordered in the structure. This is the position in SOCS3 that contains the 23 residue PEST sequence, which is deleted in our construct. In the C-terminal half of the BG loop, two segments form short, 3 residue b strands, bBG1 (residues 165-167) and bBG2 (residues 174-176), which, along with residues Thr759 (P+2) through Val761 (P+4) of the gp130 phosphopeptide, create a mini three-stranded antiparallel b sheet ( Figure 1A ). Despite the length of the BG loop, the SOCS3 SH2 domain ends like a conventional SH2 domain with the short bG (residues 180-182). This will necessarily position the 40 residue SOCS box, which directly follows (3 residue linker), on the backside of the SH2 domain, opposite the phosphopeptide binding surface ( Figure 1A, right) . Thus, it is likely that phosphotyrosine binding by the SH2 domain and elongin BC engagement by the SOCS box are independent recognition events for SOCS proteins.
Determinants of SOCS3 Binding Specificity
The crystal structure of the SOCS3D-gp130 phosphopeptide complex provides the molecular basis for understanding the phosphotyrosine binding preferences of SOCS3. In a previous biochemical study (Nicholson et al., 2000) , individual alanine substitutions of Val760 (P+3), Val761 (P+4), and His762 (P+5) resulted in 31-, 10-, and 7-fold losses of binding to SOCS3, respectively, and binding was effectively abrogated with substitution of pTyr757 (P) with tyrosine. Substitution of either Val755 (P22) or Glu756 (P21) with alanine resulted in a 5-fold loss of binding. As described above, the structural basis for the sequence selectivity at the P (pTyr757), P+3 (Val760), and P+5 (His762) positions of the phosphopeptide is evident. The contribution to binding of valine at P+4 (Val761) over alanine is likely due to the propensity of valine (with branching at the Cb atom) to adopt an extended backbone conformation (Betancourt and Skolnick, 2004; Hu and Hubbard, 2005) , rather than to van der Waals interactions (few, if any) made by the Val761 side chain. The carboxylate group of Glu756 (P21) is in the vicinity of Lys91 (bD3) (see Figure 1B , positive potential near P21 residue), although not formally within salt-bridging distance.
SOCS3 binding sites have been mapped on several other cytokine receptors, including the leptin receptor (pTyr985/1077) (Bjorbak et al., 2000; Eyckerman et al., 2000) and the erythropoietin receptor (pTyr401) (Sasaki et al., 2000) . However, the affinity of SOCS3 for these phosphorylation sites is considerably lower (>80-fold) than for pTyr757 in gp130 (De Souza et al., 2002) . Of these other sites, pTyr985 in the leptin receptor has the highest affinity (80-fold lower than gp130) (De Souza et al., 2002) , possessing a valine at P22 and a valine at P+4, but less favorable residues at P21 (lysine), P+3 (leucine), and P+5 (serine). From the crystal structure, the SOCS3 P+3 binding pocket is best fit with valine, although isoleucine could be accommodated, but leucine less so. This is in agreement with a degenerate phosphopeptide library study of SOCS3 specificity (De Souza et al., 2002) .
The SH2 domain of SOCS3 has been shown to have overlapping phosphotyrosine sequence specificity with the SH2 domains of SHP2 (De Souza et al., 2002) (see Figure 3B for a structural comparison). The residues chiefly responsible for the overlap are valine at P22 (because of the common glycine at aA2) and valine/isoleucine at P+3. Despite the presence of these residues in the sequence surrounding pTyr757 of gp130, the affinity of the interaction of gp130 with the N-and C-terminal SH2 domains of SHP2 is, respectively, 4-and 8-fold lower than for SOCS3. In addition to the overall affinity boost afforded by the interaction of the SOCS3 EF loop with the phosphopeptide backbone ( Figures 2B  and 2C ), His762 (P+5) is likely to be a key determinant in SOCS3 versus SHP2 binding. According to the phosphopeptide library study (De Souza et al., 2002) , histidine ranks highest at P+5 for SOCS3, whereas tryptophan and phenylalanine are preferred at P+5 for SHP2 (both SH2 domains). The crystal structure shows precisely why SOCS3 prefers histidine at the P+5 position ( Figures 2B  and 2C ).
An NMR solution structure of SOCS3 with bound gp130 pTyr757 phosphopeptide was recently reported (Babon et al., 2006) . Although this structure provides an overall view of the SOCS3 SH2 domain and N-terminal extension, there are significant deviations from the crystal structure ( Figure 3C) ; the overall root-meansquare deviation (rmsd) in Ca positions is 4.5 Å (115 Ca atoms, using the averaged NMR structure from 20 individual structures). An important difference between the X-ray and NMR structures concerns the SOCS3 EF loop. In the NMR structure, there is no indication of an interaction between the EF loop and the phosphopeptide (Waksman et al., 1993) , human SHP2 (N-terminal SH2, PDB code 1AYA) (Lee et al., 1994) , and murine SOCS1 (predicted). Residues shaded in purple reside in a helices, and residues shaded in cyan reside in b strands. Disordered residues not included in the atomic model are italicized. The residues in the BG loop that were deleted in the SOCS3D construct are shaded in gray. Residues of the SOCS3 and SOCS1 kinase inhibitory region are underlined. Residues colored blue make direct hydrogen bonds or salt bridges via their side chains to the phosphate group of the bound phosphopeptide (predicted for SOCS1), and residues colored red make direct hydrogen bonds via their side chains to other residues in the bound phosphopeptide (only present in SOCS3D-gp130). (B) Superposition (Ca trace) of the SOCS3D-gp130(pTyr757) structure with the N-terminal SH2 domain of SHP2 with bound phosphopeptide (PDB code 1AYA) (Lee et al., 1994) . Residues in bB, bC, and bD were used in the superposition (rmsd = 0.28 Å for 20 Ca atoms). SOCS3D is colored cyan, the gp130 phosphopeptide is colored yellow, the SHP2 N-terminal SH2 domain is colored dark green, and the bound phosphopeptide is colored light green. Select side chains of the phosphopeptides are shown in stick representation: Val (P22), pTyr (P), Val (P+3), and His (P+5) (SOCS3 structure) or Pro (P+5) (SHP2 structure). (C) Superposition (Ca trace) of the SOCS3D-gp130(pTyr757) crystal structure and the SOCS3-gp130(pTyr757) NMR structure (PDB code 2BBU) (Babon et al., 2006) . The individual NMR structure with the lowest overall rmsd (#18 in the 20-structure ensemble; rmsd = 4.3 Å for 115 Ca atoms) was used for the comparison. For the figure, residues in bB, bC, and bD were superimposed (rmsd = 1.4 Å for 23 Ca atoms). SOCS3D and the gp130 phosphopeptide from the crystal structure are colored cyan and yellow, respectively, and SOCS3 and the gp130 phosphopeptide from the NMR structure are colored dark green and light green, respectively. For clarity, the w30 residue PEST sequence at the beginning of the BG loop has been omitted from the NMR structure. The beginning/end of the omitted interval are indicated by green arrows, and the beginning/end of the disordered region of the BG loop in the SOCS3D crystal structure are indicated by cyan arrows. As in (A), select side chains of the phosphopeptide are shown in stick representation.
( Figure 3C ), whereas in the X-ray structure, there are extensive contacts ( Figures 2B and 2C) , which provide the structural basis for high-affinity binding of gp130. Removing from the superposition the EF loop and regions C-terminal (e.g., aB, BG loop), the rmsd value for the N-terminal 74 Ca atoms is still 3.6 Å (using the averaged NMR structure). A recent crystal structure of SOCS2 in complex with elongin BC (but without bound phosphopeptide) (Bullock et al., 2006) reveals an SH2 domain architecture that is very similar, up to the EF loop, to that of the SOCS3D crystal structure, with an rmsd value of only 1.3 Å for the same N-terminal 74 Ca atoms (45% sequence identity).
Implications for JAK2 Inhibition by SOCS3 and SOCS1 Tyr31 of SOCS3, which has been postulated to function as a pseudosubstrate inhibitor of JAK2 , is positioned near the beginning of aN, the N-terminal extension to the SH2 domain ( Figure 1A , right). Based on manual docking of SOCS3D to previously mapped pTyr1007 Yasukawa et al., 1999) in the activation loop of the JAK2 kinase domain (Lucet et al., 2006) , it is implausible that Tyr31 or the equivalent residue in SOCS1, Tyr65, could reach the active site of a JAK2 molecule to which its SH2 domain is bound, i.e., in cis. In the case of the verified pseudosubstrate inhibition of the insulin receptor kinase by Grb14 (Depetris et al., 2005) , the pseudosubstrate residue (Leu376) is 63 residues N-terminal to the start of the SH2 domain, compared to just 15 residues for Tyr31 of SOCS3. However, a pseudosubstrate inhibition mechanism in trans, involving two JAK2 molecules, cannot be ruled out. Moreover, from the SOCS3D-JAK2 docking exercise, the EF and BG loop extensions in SOCS3, which are not present in SOCS1-indeed, the SOCS1 BG loop is anomalously short ( Figure 3A )-would likely hinder binding of the SOCS3 SH2 domain to the intact activation loop of JAK2. This observation is consistent with the measured lower affinity for JAK2 of the SOCS3 versus SOCS1 SH2 domain .
Based on the crystal structure of SOCS3D-gp130(pTyr757) and the above-described structural considerations, the physiologic target of the SOCS3 SH2 domain is likely to be pTyr757 of gp130 (and possibly related sequences on other cytokine receptors) rather than the activation loop of JAK2. Although the exact mechanism by which SOCS3 inhibits JAK signaling is not fully resolved, one favorable hypothesis is that binding of the SOCS3 SH2 domain to pTyr757 of gp130 positions the kinase inhibitory region (pseudosubstrate or otherwise) for binding to a JAK2 molecule bound to the same gp130 receptor. Additional biochemical and structural studies will be necessary to validate this particular ''cis'' mechanism and to elucidate the precise structural mechanism by which the kinase inhibitory region of SOCS3/1 represses JAK2 catalytic activity.
Experimental Procedures Protein Expression and Purification
Residues 15-185 of murine SOCS3 was subcloned from a full-length SOCS3 cDNA kindly provided by Dr. E. Van Obberghen. The BG loop deletion (residues 131-153) was introduced by PCR amplification of the N-terminal (residues 15-130) and C-terminal (residues 154-185) fragments separately, and then by using a mixture of the two fragments as templates for PCR amplification from residue 15 to residue 185. The construct was verified by automated DNA sequencing. SOCS3D was inserted into an E. coli expression vector that includes a TEV-cleavable, N-terminal 6xHis tag. After TEV cleavage, 4 residues (GSEF) remain N-terminal to the start of the native SOCS3 sequence.
The vector encoding SOCS3D was transformed into E. coli strain BL21(DE3), and cultures were grown in Luria broth media at 37 C to an OD 600 of 0.6. Protein expression was induced by the addition of isopropyl-thiogalactopyranoside (IPTG, 0.2 mM) for 12 hr at 19 C. Cells were harvested, resuspended in lysis buffer (50 mM Tris [pH 8.0], 300 mM NaCl, 0.1% Triton X-100, 2 mg/ml aprotinin, 50 mg/ml antipain, 1 mg/ml leupeptin, and 5 mM 2-mercaptoethanol), and lysed by French press. The lysate was centrifuged at 37,000 3 g for 1 hr, and the supernatant was collected. Although SOCS3D is mostly insoluble (inclusion bodies), the soluble fraction was purified by Ni-NTA chromatography (Qiagen), followed by gel filtration chromatography (Superdex 75, Amersham). The 6xHis tag was then cleaved with TEV, and the purified SOCS3D was separated from the 6xHis tag and 6xHis-tagged TEV by passing the solution over the Ni-NTA beads. An 11 residue phosphopeptide representing the murine gp130 pTyr757 site, STVEpYSTVVHS, was synthesized (GeneMed Synthesis) and solubilized in 100 mM Tris-HCl (pH 8.0) and 150 mM NaCl. The phosphopeptide was added to SOCS3D at a 2:1 molar stoichiometry prior to concentration in a Vivaspin (Vivascience) microconcentrator.
Crystallization, X-Ray Data Collection, Structure Determination, and Refinement Crystals of the SOCS3D-gp130 phosphopeptide complex were grown at 20 C by using the hanging drop vapor diffusion method. A total of 1 ml of a stock solution of the complex at 7-12 mg/ml with a w2:1 molar excess of phosphopeptide was mixed with an equal volume of reservoir buffer containing 30% PEG 8000, 0.1 M sodium cacodylate (pH 6.5), and 0.2 M sodium acetate (Hampton Research Crystal Screen condition #28). The crystals belong to orthorhombic space group C222 1 with cell dimensions of a = 42.92 Å , b = 94.71 Å , and c = 69.92 Å . There is one complex in the asymmetric unit, yielding a solvent content of 37%.
An initial 3.2 Å resolution data set was collected on a rotating anode source (Rigaku RU-200 generator, Rigaku R-AXIS IIC image plate detector, and Rigaku Confocal Blue optics) and processed by using HKL-2000 (Otwinowski and Minor, 1997) . Previous biochemical studies had indicated that the SOCS3 SH2 domain and the C-terminal SH2 domain of SHP2 had overlapping phosphotyrosine binding specificities (Nicholson et al., 2000) . Using the structure of the C-terminal SH2 domain of SHP2 (PDB code 2SHP [Hof et al., 1998 ]) as a template, a model for the SOCS3 SH2 domain was generated by using SWISS-MODEL (Schwede et al., 2003) . The model included SOCS3 residues 46-182, with residues 106-114 (EF loop) and residues 131-175 (BG loop) omitted. Using this as a search model, a molecular replacement solution was found with AMoRe (Navaza, 1994) . The initial AMoRe solution gave a correlation coefficient (c.c.) of 30.5% and an R value of 47.8% (highest 85% of the structure factor amplitudes, 12.0-3.5 Å ), with the next highest solution at c.c. = 26.9% (R value = 48.0%). By deleting several residues in other loop segments, a c.c. of 32.0% (R value of 47.8%) was achieved (next highest solution: c.c. = 26.9%, R value = 48.8%). Using subsequent data sets at 2.7 Å resolution (rotating anode) and 2.0 Å resolution (NSLS beam line X4A; see Table 1 ), an atomic model for SOCS3D was generated from iterative rounds of building in O (Jones et al., 1991) and refinement (simulated annealing and positional/B factor) with CNS (Brü nger et al., 1998) . The final rounds of refinement were performed with REFMAC (Murshudov et al., 1997) . The model for SOCS3D includes residues 29-185 (residues 15-28 are disordered), except for residues 131-153 (BG loop, deletion), residues 155-163 (BG loop, disordered), and residues 169-172 (BG loop, disordered) .
At an intermediate stage of structure building and refinement (R value/R free of w30/34%), experimental phasing was sought. Mercury-derivatized SOCS3D-gp130 crystals were produced by soaking overnight in reservoir solution (described above) containing 1 mM ethylmercuric phosphate (EMP). The derivatized crystals were subsequently soaked in cryosolution (25% PEG 8000, 0.1 M sodium cacodylate [pH 6.5], 0.2 M sodium acetate, and 20% ethylene glycol) for 5 min to remove nonspecifically bound EMP. The crystal was then flash frozen in liquid nitrogen. A 2.3 Å data set at l = 1.0055 Å (just above the mercury L III absorption edge) was collected from a single EMP-derivatized crystal at NSLS beam line X4A (Table 1) . Data were indexed, integrated, and scaled with HKL-2000 (Otwinowski and Minor, 1997) . The native and EMP-derivatized crystals were isomorphous. Two mercury atoms in the asymmetric unit, bound to Cys97 and Cys119, were located by using SOLVE (Terwilliger and Berendzen, 1999) . SIRAS (single isomorphous replacement with anomalous scattering) experimental phases were calculated to 2.5 Å resolution with MLPHARE (Otwinowski, 1991) by using the 2.3 Å EMP data set and the 2.0 Å native data set. After real-space density modification in RESOLVE (Terwilliger and Berendzen, 1999) , the experimentally phased electron density map was of high quality and confirmed that the structure built by using model-derived phases (from the molecular replacement solution) was correct, and that much of the N-terminal region, as well as significant portions of the BG loop, was disordered. Buried surface areas in SH2-phosphopeptide complexes were computed by using CNS (Brü nger et al., 1998) (buried_surface.inp) with a probe radius of 1.4 Å (water molecules removed). Structural superpositions were performed with TOSS (Hendrickson, 1979) .
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